1. An ink jet recording liquid comprising a compound represented by the following Formula (1):
wherein each of R11, R12 and R13 in the Formula (1) represents a hydrogen atom or a substituent, and n11 represents an integer number from 1 to 3 and n12 represents an integer number from 1 to 4.
2. An ink jet recording liquid comprising a compound represented by the following Formula (2):
wherein each of R21, R22, R23 and R24 in the Formula (2) represents a hydrogen atom or a substituent, and n21 represents an integer number from 1 to 3.
3. An ink jet recording liquid comprising a compound represented by the following Formula (3):
wherein each of R31, R32, R33 and R34 in the Formula (3) represents a hydrogen atom or a substituent, and n31 represents an integer number from 1 to 3.
4. The liquid of claim 1, wherein the compound represented by the Formula (1) comprises a sulfonate group or a carboxyl group.
5. The liquid of claim 1, wherein the compound represented by the Formula (1) is contained as a fine particle dispersion material.
6. The liquid of claim 1, wherein the compound represented by the Formula (1) is contained as a fine particle dispersion material with an oil-soluble polymer.
7. The liquid of claim 2, wherein the compound represented by the Formula (2) comprises a sulfonate group or a carboxyl group.
8. The liquid of claim 2, wherein the compound represented by the Formula (2) is contained as a fine particle dispersion material.
9. The liquid of claim 2, wherein the compound represented by the Formula (2) is contained as a fine particle dispersion material with an oil-soluble polymer.
10. The liquid of claim 3, wherein the compound represented by the Formula (3) comprises a sulfonate group or a carboxyl group.
11. The liquid of claim 3, wherein the compound represented by the Formula (3) is contained as a fine particle dispersion material.
12. The liquid of claim 3, wherein the compound represented by the Formula (3) is contained as a fine particle dispersion material with an oil-soluble polymer.
13. The liquid of claim 1, wherein when n11 and n12 are two or more, two R12s or R13s are mutually bonded to form a ring.
14. The liquid of claim 2, wherein R23 and R24 are mutually bonded to form an aromatic ring.
15. The liquid of claim 2, wherein R23 and R24 are mutually bonded to form a substituted or non-substituted benzene ring.
16. The liquid of claim 2, wherein when n21 is two or more, two R22s are mutually bonded to form a ring.
17. The liquid of claim 3, wherein R33 and R34 are mutually bonded to form an aromatic ring.
18. The liquid of claim 3, wherein R33 and R34 are mutually bonded to form a substituted or non-substituted benzene ring.
19. The liquid of claim 3, wherein when n31 is two or more, two R32s are mutually bonded to form a ring.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-35. (canceled)
36. A kit comprising:
(i) at least one binding element specific for a cell surface marker, wherein said cell surface marker is: CD11b, CD15, CD16, CD34, CD45, CD33, CD14, or CD7;
(ii) at least three binding elements specific for three of the following intracellular markers: cleaved PARP, p-CHK1, p-CHK2, p-H2AX, p-ATM, or p-ATR; and
(iii) at least two of the following modulators: Etoposide, Ara-C, Daunorubicin, Gemtuzumab, Apo2LTRAIL, or FASL.
37. A kit in accordance with claim 36 further comprising:
a binding element specific for p-p53, cleaved Caspase 8, or cleaved Caspase 3; and
at least one of the following modulators: Staurosporine or TNF\u03b1.
38. A kit in accordance with claim 36, wherein the binding elements are antibodies.
39. A kit in accordance with claim 36, further comprising a control cell andor control compound.
40. A kit in accordance with claim 36, further comprising a protocol or instructions.
41. A kit in accordance with claim 36, further comprising software for data analysis.
42. A kit in accordance with claim 36, further including a fixative, permeabilizing agent, buffer, instructions, detection element, and software for data analysiscompilation.
43. A kit in accordance with claim 42, wherein the detection element comprises a fluorescent label or a label that is detectable by mass spectrometry.
44. A method for classifying cells comprising:
providing a kit in accordance with claim 36;
contacting cells with two or more of the modulators of (iii) to activate cell signaling pathways;
contacting cells with at least one of the binding elements of (i) to identify a cell type;
contacting cells with three or more of the binding elements of (ii) to identify the one or more activated cell signaling pathways; and
classifying cells based on the identified cell type and the identified one or more activated cell signaling pathways.
45. The method of claim 44, wherein the classification of cells is used in diagnosis or prognosis of a condition, or drug discovery, drug development or patient stratification for a condition.
46. The method of claim 45, wherein said condition is one of non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, non-B cell lymphomas, other lymphomas, acute or chronic leukemias, polycythemias, thrombocythemias, myelodysplastic disorders, myeloproliferative disorders, myelofibroses, atypical immune lymphoproliferations or a plasma cell disorder.
47. The method of claim 46, wherein said plasma cell disorder is multiple myeloma, amyloidosis or Waldenstrom’s macroglobulinemia.
48. The method of claim 46, wherein said one of acute or chronic leukemias is a myeloid leukemia or a lymphoid leukemia.
49. The method of claim 48, wherein said myeloid leukemia is acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), or juvenile myelomonocytic leukemia (JMML).
50. The method of claim 48, wherein said lymphoid leukemia is non-B cell acute lymphocytic leukemia (T-ALL), B cell acute lymphoblastic leukemia, or chronic lymphocytic leukemia (CLL).
51. The method of claim 45, wherein said condition is a hematologic disease or disorder selected from the group consisting of myelodysplastic disorders, myeloproliferative disorders, myelofibroses, polycythemias, thrombocythemias, B cell immunoproliferations, post transplant lymphoproliferation disorder (PTLD), and non-B atypical immune lymphoproliferations.
52. The method of claim 45, wherein said condition is CLL.
53. The method of claim 45, wherein said condition is AML.
54. The method of claim 45, wherein said condition is acute lymphocytic leukemia (ALL).
55. The method of claim 45, wherein said condition is CML.
56. The method of claim 45, wherein said condition is myelodysplastic syndrome (MDS).